Influvac Tetra

B/Phuket/3073/2013‑Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202, the active ingredient in Influvac Tetra, is a vaccine presented as an injectable solution for intramuscular or subcutaneous use. It is intended to prevent influenza infection caused by the virus strains included in the vaccine, primarily in individuals aged six months and older.

GNH USA supplies Influvac Tetra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Influvac Tetra is a quadrivalent influenza vaccine used to prevent seasonal influenza caused by the four virus strains it contains. - Seasonal influenza: reduces the risk of infection with the four influenza virus strains included in the vaccine. - Children ≥6 months: provides active immunity against circulating influenza B strains. - Adults and elderly: helps prevent influenza‑related complications and hospitalisation. - High‑risk groups (e.g., chronic disease patients): lowers the likelihood of severe flu outcomes. - Healthcare workers: contributes to occupational health by reducing transmission risk.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Low‑grade fever: transient temperature rise within 24‑48 hours. - Headache or malaise: general feeling of tiredness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder potentially triggered post‑vaccination. - High fever or seizures: especially in young children. - Myocarditis or pericarditis: inflammation of heart muscle or surrounding tissue.

Influvac Tetra should be administered with consideration of the following precautions. - Allergy assessment: avoid if known severe allergy to any vaccine component. - Prior severe reaction: defer vaccination in individuals who experienced a serious adverse event after a previous influenza vaccine. - Immunocompromised patients: vaccine may elicit a reduced immune response; consult healthcare provider. - Pregnancy: use only if the potential benefits outweigh uncertain risks, as safety data are limited. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Influvac Tetra has limited known drug interactions, but certain co‑administered therapies may affect its efficacy. Major Interactions (Avoid): - None identified: no known drug interactions requiring avoidance.

Moderate Interactions (Monitor Closely): - Concurrent immunoglobulin therapy: may reduce vaccine immunogenicity; consider timing separation. - Antipyretics before vaccination: may blunt antibody response; use after vaccination if needed. - Live attenuated vaccines given within 4 weeks: monitor for potential immune interference.